This webinar presented by QPS Neuropharmacology discussed validated transgenic and non-transgenic in vitro and in vivo models covering most targets of Alzheimer's, Parkinson's, Huntington's, and other neurodegenerative diseases.
- When to use animal models in your drug discovery program
- How to choose the most appropriate animal model for your therapeutic or mechanism of action
- How to design the most efficient "first-pass" proof-of-concept study
- Best practices for submitting compounds and sample requirements for a successful study
About the Speaker
Birgit Hutter-Paier, PhD, is the Director of Neuropharmacology at QPS Austria. She has extensive experience in life science research and development, covering drug discovery and project management and directing multiple diverse, concurrent projects from ranging from early preclinical stages to pharmacology. She has created state-of-the-art labs as well as a behavioral pharmacology testing facility. Dr. Hutter-Paier established and managed the preclinical research group, with whom she develops transgenic and non-transgenic mouse models, mainly in Alzheimer's and Parkinson's disease research.
Brought to you by ADDF ACCESS, a program of the ADDF and Science Exchange, as part of our commitment to connect ADDF researchers with technologies that can help accelerate breakthrough discoveries.